ACAD — ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. (ACAD) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q4 2025 Adjusted Total Revenues: $298 million, up 16% year-over-year.
• Full Year 2025 Adjusted Revenues: $1.08 billion, a 14% increase from 2024.
• NUPLAZID Net Sales: Q4 adjusted net sales of $189 million (up 17% YoY) and full-year adjusted net sales of $692 million (up 15% YoY).
• DAYBUE Net Sales: Q4 net sales of $110 million (up 13% YoY) and full-year net sales of $391 million (up 12% YoY).
• Operating Expenses: R&D expenses decreased to $85 million in Q4 from $101 million in Q4 2024, while SG&A expenses increased to $156 million from $130 million.
• Cash Balance: $820 million at year-end 2025.
• Tax Benefit: A one-time noncash income tax benefit of approximately $250 million was recorded.

2. Strategic Updates and Business Highlights:

• ACADIA achieved its first-ever annual revenue exceeding $1 billion, driven by strong commercial execution.
• NUPLAZID continues to show robust growth, with volume increases and new prescriptions up 18% YoY in Q4.
• DAYBUE's growth is attributed to expanded access in community settings and the upcoming launch of DAYBUE STIX, a new powder formulation.
• The company is advancing its R&D pipeline, with several Phase II and Phase III studies planned, including a Phase II readout for remlifanserin expected between August and October 2026.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Total revenues expected between $1.22 billion and $1.28 billion.
• NUPLAZID Guidance: Projected net sales of $760 million to $790 million, indicating 10% to 14% growth over 2025.
• DAYBUE Guidance: Expected net sales between $460 million and $490 million, reflecting 18% to 25% growth over 2025.
• The company anticipates achieving blockbuster status for NUPLAZID with $1 billion in net sales by 2028.

4. Bad News, Challenges, or Points of Concern:

• Regulatory challenges in the EU for DAYBUE, with a negative trend vote from the CHMP regarding its marketing application, leading to a planned request for reexamination.
• The impact of the Inflation Reduction Act on NUPLAZID's net sales, necessitating adjustments in accounting estimates for rebates, which could affect future cash flows.
• Potential competition from other treatments, particularly in the Alzheimer's disease psychosis space, which may impact the market share of remlifanserin.

5. Notable Q&A Insights:

• Management expressed confidence in achieving 2028 sales targets for both NUPLAZID and DAYBUE, with expected growth driven by new product formulations and expanded market access.
• Concerns were raised regarding the execution of clinical trials and the potential for placebo effects in upcoming studies for remlifanserin.
• The company is focused on maintaining compliance and monitoring for any irregularities in clinical trial execution, ensuring adherence to good clinical practices.
• There is optimism about the potential for DAYBUE STIX to unlock additional patient populations, with estimates suggesting it could capture over 400 new patients over the next few years.

Overall, ACADIA Pharmaceuticals reported strong financial performance in Q4 2025, with positive growth trajectories for its key products, while also navigating regulatory challenges and competitive pressures in the market.